The Experts in Animal Health

print version

Brakke Consulting’s
Animal Health News & Notes for April 10, 2015

Copyright © Brakke Consulting, Inc.
Editor: Lynn Fondon DVM MBA
Brakke Consulting news
Pharmaceutical Market Shift study
strategic planning
earnings news
other news
Aspen Veterinary Resources
Assisi Animal Health
Belcher Pharmaceuticals
Boehringer Ingelheim
Paladin Labs
Partner in Pet Food
Purina Animal Nutrition

The KC Animal Health Corridor is now accepting applications to present at the 2015 KC Animal Health Investment Forum on September 1 in Kansas City, Missouri.

Now in its seventh year, the Forum is one of the only opportunities in the world for early-stage companies in the animal health sector to present their vision, business plan and technology to potential investors.

The selection committee will consider companies that meet the following criteria:
– Seeking $500,000 – $20 million in funding
– Revenue projections of $20 million within 5-7 years

Applications are due on April 17. To apply, go to For more information, contact Kimberly Young at
> Nippon Zenyaku Kogyo (Zenoaq) reported results for the full year ended March 31, 2015. Revenues were ¥24,285 million ($206 million), a 5% decline in sales compared to the prior fiscal year. (Animal Pharm)

Brakke Consulting and Trone Brand Energy announce the publication of the 2015 Pet Pharmaceutical Market Shift Study. The report, based on extensive interviews and surveys of pet owners, veterinarians, and pharmacists, documents the changes in the pharmaceutical buying behavior of pet owners.

Among the key findings, the study identified:
• Which segments of pet owners have already modified their buying behavior for pet pharmaceuticals
• How many pet owners plan to change in the future
• What pet owners expect from their veterinarian
• The implications of veterinarians resisting those pet owner expectations

The study is now available. Companies wishing to purchase, or find out more about the completed study, can contact: David B Goodnight, DVM MBA, (830) 285-1259,
> The FDA announced it has approved Putney’s generic Tiletamine-Zolazepam injectable solution for use in cats and dogs for restraint and anesthesia. (FDA) 
> The FDA announced it has approved Belcher Pharmaceuticals’ generic Carprofen Flavored Tablets for the relief of pain and inflammation in dogs. (FDA) 
> Aspen Veterinary Resources, Ltd, an Animal Health International company, announced the launch of Vetameg Equine Paste (flunixin meglumine), indicated for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. (Vet Advantage)  
> Assisi Animal Health announced the launch of their second generation Loop, the Assisi Loop 2.0. The new Loop 2.0, offered in two sizes, is a patented, targeted pulsed electromagnetic field (tPEMF) device, prescribed by veterinarians for pain and inflammation, either alone or in combination with NSAIDs and other agents. ( 
> The FDA announced it has withdrawn the approval for Antizol-Vet (fomepizole) antidote for ethylene glycol (antifreeze) poisoning in dogs, at the request of Paladin Labs, the drug’s sponsor. Paladin requested the withdrawal because the company has not manufactured or marketed the drug since October 1, 2014. (FDA CVM) 
> Human pharma company Mylan Inc. has made a $29 billion acquisition bid for Perrigo, which recently acquired Sergeant’s Pet Care Products and Velcera. The company has offered Perrigo shareholders $205 in a combination of cash and Mylan stock per share. This represents a premium of more than 25% compared to Perrigo’s trading price on April 3. Perrigo said its board will meet to discuss the proposal. Mylan is focused on developing generics but has no animal health division. (Animal Pharm) 
> Purina Animal Nutrition announced the launch of Purina DRY COW and Purina PRE-FRESH Programs, a complete line of minerals, supplements and complete feeds for dry and pre-fresh cows. (Vet Advantage – Hoard’s Dairyman) 
> EU  Boehringer Ingelheim announced that Vetmedin Chewable Tablets have been licensed in the EU for treating pre-clinical dilated cardiomyopathy (DCM) in Doberman Pinschers. (
> EU  Advent International announced that Partner in Pet Food (PPF) has been acquired by global private equity investment firm Pamplona Capital Management for EUR 315 million ($343 million). Pamplona is backing PPF’s current management team and will continue to invest in the business to support organic growth. ( 
> US – CANINE INFLUENZA   Illinois’ Cook County Department of Animal and Rabies Control has reported that more than 1,000 dogs in the Chicago area have become sick and five have died as a result of canine influenza. In addition to vaccination, veterinarians are recommending limiting pet interaction until the epidemic has subsided. (
> US – AVIAN INFLUENZA  The H5N2 strain of avian influenza has reached the Midwest US, killing or requiring hundreds of thousands of turkeys to be euthanized. Minnesota has been hit harder than any other state, with outbreaks at eight turkey farms in central and western Minnesota since late February, as well as farms in the Mississippi and Central flyways in Missouri, South Dakota, North Dakota, Kansas, and Arkansas. Nearly all the losses have been at big commercial turkey farms. (ABC News)
> US – DOG BREEDING STANDARDS  The Purdue University Center for Animal Welfare Science is developing and testing uniform care standards for dog breeding and raising over the next two years. Whether the dogs are raised for sale as pets or for research, compliance with the standards would meet the dogs’ needs for socialization, enrichment, and comfort and include well-being assessment. The USDA’s Animal and Plant Health Inspection Service is supporting the effort, and the agency earlier this year included creation of a private accreditor program for professional dog breeders among its goals for the next five years. (APPA enews)
> US – DISEASE RESEARCH  The College of Veterinary Medicine at Kansas State University announced it is establishing the Center of Excellence for Vector-Borne Diseases (CEVBD). CEVBD is an interdisciplinary research center with a mission to combat vector-borne diseases with a focus on pathogenesis, surveillance and disease prevention in both animals and people. CEVBD goals include establishing a tick-rearing facility to support the research needs of Kansas State University and other academic institutions and industry in the US. (Feedstuffs)
> US – VETERINARY-CLIENT RELATIONSHIPS  The US Court of Appeals for the Fifth Circuit rejected an appeal made by Ronald Hines, DVM, that challenged a Texas rule that requires veterinarians to conduct patient physical exams before practicing veterinary medicine. The US Court of Appeals found that a Veterinarian-Client-Patient-Relationship (VCPR) cannot be established solely by telephone or electronic means. (Vet Advantage – AAHA NEWStat)

Brakke Consulting is an excellent resource for your company’s strategic planning. Some of the services we offer include:
– Reviewing revenue estimates and success probability of your product pipeline.
– Reviewing the timing of various new product introductions and estimate the impact of various scenarios.
– Benchmarking various functions against company competitors in the larger markets, which might include sales force size, technical services and/or R&D spending vs. sales.

Through strategic planning, Brakke Consulting can help improve the likelihood of success for your company’s future endeavors.

Contact us for professional assistance in any of these areas.
This week’s news reflects a reasonably large number of activities or results in various forms. There were some new generic drug approvals by the FDA for products in the companion animal area. The recent number of generic drug approvals versus new animal drug approvals reflects the difficulty and cost of researching and developing innovative products for the animal health industry. It is our observation that a number of these generic product approvals will be in product categories already reasonably well served. So, in order to obtain market share there will be pricing or revenue pressure which could take revenue out of the industry.

It should also be noted that a major human generics company announced an offer to purchase another human generic drug company with a stake in animal health for $29 billion. Assuming this transaction closes, this will bring one of the largest human generic drug companies into the animal health market space. When you couple the generic drug company activity with some of the findings in our recent Pet Pharmaceutical Market Shift Study, one can begin to see where this industry could be headed. These will continue to be interesting times!

Have a good weekend!!
Ron Brakke
This electronic newsletter is the sole property of Brakke Consulting, Inc.
Any use of the contents herein should be approved by and appropriately attributed to Brakke Consulting, Inc.
For more information about Brakke Consulting’s services and syndicated studies, visit our website at
Brakke Consulting, Inc.
12005 Ford Rd., Suite 530
Dallas, TX  75234    USA

en_USEnglish (United States)